Neos Therapeutics, Inc. (Neos), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, has been granted a patent covering its novel amphetamine ADHD products.

Neos has developed an extended release (XR) amphetamine oral disintegrating tablet (ODT) and an extended release amphetamine liquid suspension both of which are expected to be filed for FDA approval in the next 12-15 months. “We are pleased with the grant of this patent as it will provide protection for our amphetamine XR-ODT and amphetamine XR-suspension until June 2032,” said Vipin K. Garg, chief executive officer of Neos. “We have begun to assess our options to commercialize these products in anticipation of FDA approval.”

“The Neos patent portfolio continues to grow as we continue to develop and utilize our platform drug delivery technologies,” stated Mark Tengler, chief t officer of Neos. “Extended release and patient-friendly dosage forms are essential in the treatments of ADHD, and our technologies may provide this advantage.”

Dynamic Time Release Suspension and DTRS are registered trademarks of Neos Therapeutics, LP, an affiliate of Neos Therapeutics, Inc., and Rapidly Disintegrating Ionic Masking and RDIM are trademarks of Neos Therapeutics, Inc.

Neos Therapeutics Inc., is a specialty pharmaceutical company focused on the development and manufacture of FDA approved drug products that utilize the company’s proprietary and patented delivery technologies.